Latest Biothorpe Pharmaceuticals Stories

US-based biotechnology company ZaBeCor Pharmaceuticals has announced the formation of its new subsidiary Biothorpe Pharmaceuticals, a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer. Biothorpe's intellectual property portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase. Biothorpe intends to license its intellectual property for the treatment of three cancers - acute...

ZaBeCor Pharmaceuticals ("ZaBeCor") announces today the formation of its new subsidiary Biothorpe Pharmaceuticals ("Biothorpe" or the "Company"), a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer. Recent studies in academia and in the biopharmaceutical industry indicate that Syk kinase is required for the proliferation of malignant cells in several cancers. Biothorpe's intellectual property portfolio includes...